These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 25246772

  • 1. Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen.
    Helmschrott M, Beckendorf J, Akyol C, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Ehlermann P, Bruckner T, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2014; 8():1307-14. PubMed ID: 25246772
    [Abstract] [Full Text] [Related]

  • 2. Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation.
    Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2015; 9():1217-24. PubMed ID: 25759566
    [Abstract] [Full Text] [Related]

  • 3. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Cao S, Cox KL, Berquist W, Hayashi M, Concepcion W, Hammes GB, Ojogho OK, So SK, Frerker M, Castillo RO, Monge H, Esquivel CO.
    Pediatr Transplant; 1999 Feb; 3(1):22-6. PubMed ID: 10359027
    [Abstract] [Full Text] [Related]

  • 4. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation.
    Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA.
    Drug Des Devel Ther; 2013 Feb; 7():1253-8. PubMed ID: 24174870
    [Abstract] [Full Text] [Related]

  • 5. Impact of tacrolimus versus cyclosporin A on renal function during the first year after heart transplant.
    Shiraishi Y, Amiya E, Hatano M, Katsuki T, Bujo C, Tsuji M, Nitta D, Maki H, Ishida J, Kagami Y, Endo M, Kimura M, Ando M, Shimada S, Kinoshita O, Ono M, Komuro I.
    ESC Heart Fail; 2020 Aug; 7(4):1842-1849. PubMed ID: 32445260
    [Abstract] [Full Text] [Related]

  • 6. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
    Guethoff S, Meiser BM, Groetzner J, Eifert S, Grinninger C, Ueberfuhr P, Reichart B, Hagl C, Kaczmarek I.
    Transplantation; 2013 Feb 27; 95(4):629-34. PubMed ID: 23423270
    [Abstract] [Full Text] [Related]

  • 7. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
    Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2015 Feb 27; 9():93-102. PubMed ID: 25552900
    [Abstract] [Full Text] [Related]

  • 8. Role of dendritic cells in the context of acute cellular rejection: comparison between tacrolimus- or cyclosporine A-treated heart transplanted recipients.
    John K, Dieterlen MT, Tarnok A, Garbade J, Bittner HB, Mohr FW, Barten MJ.
    Cytometry B Clin Cytom; 2014 Sep 27; 86(5):362-7. PubMed ID: 24668729
    [Abstract] [Full Text] [Related]

  • 9. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine.
    Castel MA, Farrero M, Vallejos I, Cardona M, Regueiro A, Pérez-Villa F.
    Transplant Proc; 2011 Sep 27; 43(6):2244-6. PubMed ID: 21839245
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Transpl Immunol; 2014 Aug 27; 31(2):87-91. PubMed ID: 24932812
    [Abstract] [Full Text] [Related]

  • 11. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S, Stroeh K, Grinninger C, Koenig MA, Kleinert EC, Rieger A, Mayr T, von Ziegler F, Reichart B, Hagl C, Schramm R, Kaczmarek I, Meiser BM.
    J Heart Lung Transplant; 2015 May 27; 34(5):634-42. PubMed ID: 25701373
    [Abstract] [Full Text] [Related]

  • 12. A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation.
    Sánchez-Lázaro IJ, Almenar L, Martínez-Dolz L, Buendía-Fuentes F, Agüero J, Navarro-Manchón J, Vicente JL, Salvador A.
    Clin Transplant; 2011 May 27; 25(4):606-13. PubMed ID: 20682020
    [Abstract] [Full Text] [Related]

  • 13. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y.
    Transplantation; 2012 Feb 27; 93(4):437-43. PubMed ID: 22228415
    [Abstract] [Full Text] [Related]

  • 14. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.
    Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine JL, Squifflet JP, Vialtel P, Abramowicz D, Mourad G, Wolf P, Cassuto E, Moulin B, Rifle G, Pruna A, Merville P, Mignon F, Legendre C, Le Pogamp P, Lebranchu Y, Toupance O, Hurault De Ligny B, Touchard G, Olmer M, Purgus R, Pouteil-Noble C, Glotz D, Bourbigot B, Leski M, Wauters JP, Kessler M.
    Transplantation; 2003 Mar 27; 75(6):844-51. PubMed ID: 12660513
    [Abstract] [Full Text] [Related]

  • 15. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW.
    Clin Transplant; 1997 Aug 27; 11(4):299-312. PubMed ID: 9267719
    [Abstract] [Full Text] [Related]

  • 16. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience.
    Ayar Y, Ersoy A, Ocakoglu G, Yildiz A, Oruc A, Soyak H, Calapkulu M, Sahin AB, Topal NB, Okeer E, Coskun B, Kaygisiz O, Kordan Y, Vuruskan H.
    Transplant Proc; 2017 Mar 27; 49(2):270-277. PubMed ID: 28219583
    [Abstract] [Full Text] [Related]

  • 17. Tacrolimus has immunosuppressive effects on heavy/light chain pairs and free light chains in patients after heart transplantation: A relationship with infection.
    Lavríková P, Sečník P, Kubíček Z, Jabor A, Hošková L, Franeková J.
    Transpl Immunol; 2018 Oct 27; 50():43-47. PubMed ID: 29913223
    [Abstract] [Full Text] [Related]

  • 18. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
    Lee YJ, Kim B, Lee JE, Kim YG, Kim DJ, Kim SJ, Joh JW, Oh HY, Huh W.
    Transpl Int; 2010 Feb 27; 23(2):147-54. PubMed ID: 19744223
    [Abstract] [Full Text] [Related]

  • 19. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.
    Neu AM, Ho PL, Fine RN, Furth SL, Fivush BA.
    Pediatr Transplant; 2003 Jun 27; 7(3):217-22. PubMed ID: 12756047
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May 27; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.